Oral semaglutide cuts major heart risks in people with type 2 diabetes by 14%, offering a powerful pill-based option. Both ...

We are the first Royal Society of Chemistry journal to be gold open access from launch – allowing a global, interdisciplinary network of nanoscale researchers free access to quality, field-advancing ...

Researchers reviewed data from more than 56 million pregnancies to examine the connection between diabetes and A.D.H.D., autism and intellectual disability. By Alisha Haridasani Gupta and Nina ...

Setting, participants and outcome measures Electronic databases, MEDLINE and Embase, were searched for validation studies where an administrative case definition (using ICD codes) for diabetes in ...

This makes them a high source of protein for people with diabetes. Eggs are a suitable food for people with diabetes. Having a low glycemic index score means that they have less of an effect on a ...

To recognize individuals for their outstanding achievements in the field of organic chemistry. This two-year postdoctoral fellowship will provide intellectual and academic freedom to early-career ...

Novo Nordisk on Saturday said its diabetes pill Rybelsus showed cardiovascular benefits in a late-stage trial, paving the way for it to become a new treatment option for people living with ...

Semaglutide, the medication better known as Ozempic, reduces the symptoms of a condition that can lead to lower limb amputations in people with diabetes, according to a new study that reinforces ...

The cardiovascular safety of oral semaglutide, a glucagon-like peptide 1 receptor agonist, has been established in persons with type 2 diabetes and high cardiovascular risk. An assessment of the ...

CHICAGO, IL—High-risk patients who have type 2 diabetes plus established atherosclerotic cardiovascular disease (ASCVD), chronic kidney disease (CKD), or both have significantly fewer major adverse ...

The CDK is an open-source Java library for cheminformatics and bioinformatics. The CDK is a class library intended to be used by other programs, it will not run as a stand-alone program. The library ...

- Zimislecel (VX-880) pivotal trial on track to complete enrollment and dosing in H1 2025; Vertex expects to submit marketing applications to global regulators in 2026 - Vertex has completed ...